Circulate Health Secures Strategic Investment From Scrum Ventures

Funding will expand the company’s therapeutic plasma exchange center network and accelerate longevity research

Circulate Health has received a strategic investment from Scrum Ventures to accelerate its expansion in the longevity market, including growth of its national network of Therapeutic Plasma Exchange (TPE) treatment centers and continued advancement of its research initiatives.

The company said the new capital will be used to broaden access to its plasma-based therapy offering by supporting the build-out of additional U.S. treatment locations, while also funding ongoing clinical and scientific work focused on measurable outcomes in aging and healthspan. Scrum Ventures is an early-stage venture capital firm focused on sports, human performance, and emerging health technologies—an investment thesis that aligns with Circulate’s positioning at the intersection of longevity science and performance-oriented care.

The investment builds on Circulate’s previously announced 12 million dollar seed round earlier this year, which the company said was intended to accelerate its longevity research agenda and expand its TPE footprint across the country.

Circulate has also highlighted recently reported clinical trial results evaluating TPE combined with intravenous immunoglobulin. The company said the protocol reduced biological age by an average of 2.6 years, as measured by multi-omics biomarkers. The study was conducted in collaboration with the Buck Institute for Research on Aging and was published in Aging Cell.

Circulate said the Scrum Ventures investment reflects growing interest in longevity science and will help the company scale both its clinical presence and its evidence-generation work as it continues evaluating plasma-based approaches and their potential role in broader aging research and therapeutic development.